Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534868 | 0.87 | TDP1 (0.55) | TDP1TSHRALDH1A1PTPN1APOBEC3G | |
| SCHEMBL31203 | 0.87 | TDP1 (0.55) | TDP1TSHRALDH1A1PTPN1APOBEC3G | |
| Bromide SCHEMBL8311140 | 0.84 | POLB (0.37) | TDP1TSHRALDH1A1TRPA1APOBEC3G | |
| SCHEMBL15960323 | 0.84 | TRPA1 (0.43) | TDP1TSHRALDH1A1TRPA1TAAR1 | |
| SCHEMBL29382225 | 0.81 | TSHR (0.50) | TDP1TSHRALDH1A1TRPA1PTPN1 | |
| SCHEMBL28289 | 0.81 | TSHR (0.50) | TDP1TSHRALDH1A1TRPA1PTPN1 | |
| SCHEMBL5497045 | 0.80 | TSHR (0.36) | TDP1TSHRALDH1A1TRPA1APOBEC3G | |
| SCHEMBL32679673 | 0.79 | TDP1 (0.48) | TDP1TSHRALDH1A1TRPA1PTPN1 | |
| SCHEMBL30563551 | 0.79 | APOBEC3G (0.48) | TDP1TSHRALDH1A1PTPN1APOBEC3G | |
| SCHEMBL27891 | 0.79 | APOBEC3G (0.48) | TDP1TSHRALDH1A1PTPN1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| CN-1914173-A | Quinolines useful in treating cardiovascular disease | WYETH CORP (US) | 2007-02-14 | — | — | CN | disclosed |
| US-5476846-A | Administering anti-thrombotic and anti-asthmatic agent | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-12-19 | — | — | US | disclosed |
| US-5387709-A | Bronchodilator agents, anticoagulants, vasodilation | LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0472449-B1 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA (FR) | 1994-09-14 | — | — | EP | disclosed |
| EP-0472449-A2 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | TDP1 495/4885TSHR 3447/4885ALDH1A1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.